26-07-2018 дата публикации
Номер: US20180207295A1
The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases. 1. A method of treating cancer in a patient in need thereof , the method comprising administering to the patient a pharmaceutically effective amount of a composition comprising an mRNA encoding IL-12 , IL-18 , IL-23 or OX4OL.2. The method of claim 1 , wherein administering comprises intratumoral application of the composition.3. The method of claim 2 , wherein intratumoral application of the composition comprises injection of the composition into the cancerous tissue.4. The method of claim 1 , further comprising the administration of at least a second anticancer therapy.5. The method of claim 4 , wherein the second anticancer therapy is a chemotherapy claim 4 , a hormone therapy claim 4 , an immunotherapy claim 4 , a checkpoint modulator therapy claim 4 , a cytokine therapy claim 4 , a radiation therapy claim 4 , and/or a surgery.6. The method of claim 5 , wherein the checkpoint modulator therapy is selected from the group consisting of a PD-1 inhibitor claim 5 , a PD-L1 inhibitor claim 5 , a CTLA-4 inhibitor claim 5 , a LAG3 inhibitor claim 5 , a TIM3 inhibitor claim 5 , an OX-40 stimulator claim 5 , a 4-1BB stimulator claim 5 , a CD40L stimulator claim 5 , a CD28 stimulator claim 5 , and a GITR stimulator.7. The method of claim 5 , wherein the checkpoint modulator therapy is selected from the group consisting of an agonistic antibody claim 5 , an antagonistic antibody claim 5 , a dominant negative receptor claim 5 , a decoy receptor claim 5 , and a ligand.8. The method of claim 7 , wherein the antagonistic antibody is directed against PD-1 claim 7 , PD-L1 claim 7 , or CTLA-4.9. The method of claim 7 , wherein the decoy receptor is a soluble PD-1 receptor.10. The method of claim 7 ...
Подробнее
